Showing results (91-100 of 152) with videos related to
Sort By:
Pageof 16
Experimental and Clinical Endocrinology|January 1, 1994
Plasma levels of benperidol, prolactin, and homovanillic acid after intravenous versus two different kinds of oral application of the neuroleptic in schizophrenic patientsW Seiler, H Wetzel, A Hillert, et al.Pharmacopsychiatry|December 6, 2013
Therapeutic drug monitoring of zuclopenthixol in a double-blind placebo-controlled discontinuation study in adults with intellectual disabilities and aggressive behaviourV Schwarz, O Reis, T Glaser, et al.Biological Psychiatry|October 15, 1990
Formation and metabolism of catecholestrogens in depressed patientsM Banger, C Hiemke, R Knuppen, et al.Psychopharmacology|February 1, 1995
The neuroendocrinological profile of roxindole, a dopamine autoreceptor agonist, in schizophrenic patientsG Gründer, H Wetzel, A Hillert, et al.European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|August 1, 1996
Acute, subchronic and discontinuation effects of zopiclone on sleep EEG and nocturnal melatonin secretionK Mann, H Bauer, C Hiemke, et al.European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|February 3, 1999
Combination treatment with clozapine and paroxetine in schizophrenia: safety and tolerability data from a prospective open clinical trialI Anghelescu, A Szegedi, S Schlegel, et al.Journal of Chromatography|April 19, 1991
Determination of benperidol and its reduced metabolite in human plasma by high-performance liquid chromatography and electrochemical detectionS Süss, W Seiler, C Hiemke, et al.Psychoneuroendocrinology|March 22, 2000
Effects of subchronic paroxetine administration on night-time endocrinological profiles in healthy male volunteersR Schlösser, H Wetzel, H Dörr, et al.Pharmacopsychiatry|August 23, 2013
Agomelatine and hepatotoxicity: implications of cumulated data derived from spontaneous reports of adverse drug reactionsM Gahr, R W Freudenmann, B J Connemann, et al.Pharmacopsychiatry|March 22, 2003
Melperone is an inhibitor of the CYP2D6 catalyzed O-demethylation of venlafaxineM Grözinger, A Dragicevic, C Hiemke, et al.Pageof 16